MGX

0.56507.95%
LE

Laurence E. Reid

Independent Director

Dr. Laurence E. Reid, Ph.D. was Chairman of Broken String Biosciences Ltd. He had been a Director of Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) since August 2025 and serves as its Independent Director. He is an Independent Director of KalVista Pharmaceuticals, Inc. since November 26, 2024. Dr. Reid serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since November 2019 until October 2020. Dr. Reid served as an Entrepreneur-in-Residence at Third Rock Ventures, LLC since November 2019 until November 2020. He first joined Third Rock in 2015. In addition to his professional interests, he is a Board Member of the Possible Project and Board advisor to Life Science Cares. Dr. Reid had been the Chief Executive Officer of Warp Drive Bio, LLC since March 2015 until October 2018 and served as its President. Dr. Reid served as the Chief Business Officer and Senior Vice President of Alnylam Pharmaceuticals, Inc. from June 2010 to December 31, 2014. He serves as Director of Garuda Therapeutics, Inc. since January 2022. He served as the Chief Business Officer at Ensemble Therapeutics Corporation (also known as Ensemble Discovery Corporation) since March 2006 and served as its Head of Business Development and Corporate Development, experience in the global biopharmaceutical industry, with a focus on building innovative companies. His experience includes general management, strategic planning, commercial development and business development. He served as the Chief Executive Officer of a seed stage venture focused in the fields of inflammation and pain. He founded two start-up companies in the fields of stem cell therapeutics and inflammation. Prior to this, he spent more than several years at Millennium Pharmaceuticals. Joining Millennium Pharmaceuticals as an early Employee in 1993, he advanced through a succession of positions of increasing responsibility at Millennium, initially in business development and served as General Manager of Millennium Pharmaceuticals, Ltd. from 2001 to 2003, with responsibility for Millennium's European operations and as spokesperson to the European Investor and media communities, where he was the Senior Millennium Representative in Europe, providing the overall business strategy and leadership to Millennium's Cambridge, UK drug discovery and development operation. From 1998 to 2001, he served as Vice President of Business Development and Strategic Planning for Ensemble Discovery Corporation's predictive medicine efforts. Prior to 1998, he held various roles at Millennium in pharmaceutical business development and technology acquisition. He was an Assistant Editor of the Journal Cell. Dr. Reid has a B.A. from Cambridge University in Natural Sciences with specialization in genetics and molecular biology and Broad studies in biochemistry, chemistry, physics in the year 1982 to 1985 and a Ph.D. in Molecular Biology and Biochemistry from London University in the year 1985 to 1989.

Positions